- AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
- BioAtla’s Mecbotamab Vedotin (Mec-V) Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™
- Calidi Biotherapeutics Presents New Data on CLD-401
- Coherus Oncology Presents Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
- Compugen presents trial in progress of the first in human clinical trial of COM503 (GS-0321) in participants with advanced solid malignancies
- CREATE Medicines Announces Positive First-in-Human Results for MT-302 in solid tumors
- Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform
- Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P
- Evaxion presents new immune data from phase 2 trial with EVX-01
- Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study
- Forlong Biotechology Presents Clinical Data from FL115
- Ivonescimab + Chemo Demonstrates a Statistically Significant Benefit in OS with a Hazard Ratio of 0.74 in 2L+ EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
- Marengo Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Ph 2 Trial
- MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors
- New Ph 1 Immunological Data Supports TG4050’s Potential Role in Preventing Cancer Relapse
- New Ph 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and NSCLC
- Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
- OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
- Replimune’s Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure
- Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080 in Patients with Advanced Solid Tumors
- Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden